v3.25.1
REVENUES (Tables)
 3 Months Ended
Mar. 31, 2025
Disaggregation of Revenue [Line Items]  
Disaggregation of Revenue [Table Text Block] The Company’s revenues by segment and by payers/customer groups were as follows:
Three Months Ended March 31, 2025Three Months Ended March 31, 2024
North AmericaEuropeOtherTotalNorth AmericaEuropeOtherTotal
Payer/Customer
Dx
   Clients24 %— %— %24 %25 %— %— %25 %
   Patients10 %— %— %10 %10 %— %— %10 %
   Medicare and Medicaid8 %— %— %8 %8 %— %— %8 %
   Third party36 %— %— %36 %35 %— %— %35 %
Total Dx revenues by payer78 %— %— %78 %78 %— %— %78 %
BLS
Pharmaceutical, biotechnology, and medical device companies9 %9 %4 %22 %9 %9 %4 %22 %
Total Revenues
87 %9 %4 %100 %87 %9 %4 %100 %
Revenues in the United States (U.S.) were $2,813.8 (84.1%) and $2,654.6 (83.6%) for the three months ended March 31, 2025, and 2024, respectively.
Contract with Customer, Asset and Liability [Table Text Block]
March 31, 2025December 31, 2024
Dx accounts receivable$1,403.2 $1,259.3 
BLS accounts receivable758.6 729.5 
Less BLS allowance for credit losses(38.6)(44.7)
Accounts receivable, net$2,123.2 $1,944.1 
Gross unbilled services$158.8 $160.5 
Less reserve for unbilled services(7.5)(7.6)
Unbilled services$151.3 $152.9 
Financing Receivable, Allowance for Credit Loss [Table Text Block] The rollforward for the allowance for credit losses is as follows:
Accounts ReceivableUnbilled ServicesTotal
Allowance for credit losses at December 31, 2024$44.7 $7.6 $52.3 
Write offs(6.8)(0.2)(7.0)
Foreign currency impact
0.7 0.1 0.8 
Allowance for credit losses at March 31, 2025$38.6 $7.5 $46.1